NEW YORK: Omnicom Group saw a 2.9% organic revenue increase in its healthcare work in Q3 to $262.9 million.

In the first nine months of 2018, the healthcare segment reported a 3.5% organic revenue increase to $772 million.

The segment reported double-digit revenue increases in both periods on an as-reported basis, with revenue up 10.5% and 10.4% in Q3 and the first nine months of the year, respectively. (Organic revenue growth represents change without taking into account the impact of acquisitions and disposals).

Omnicom’s healthcare-focused firms include Biolumina, CDM, DDB Health, Harrison and Star, and TBWA\WorldHealth in the professional category; Adelphi Group, and Synergy in medical, evidence, and regulatory, and HealthWork and MMG in patient and consumer.

Revenue for the holding company as a whole was up 2.9% organically compared with Q3 2017 to $3.7 billion, but down 0.1% on a non-organic basis in the period. Omnicom’s operating profit increased by 6.8% to $502.3 million in the period, while net income grew by 13.4% to $298.9 million.

Omnicom’s other business segments achieved organic revenue gains in the quarter, barring CRM execution and support, which saw a revenue drop of 3.6% to $465.6 million. Advertising was up 4% to $1.9 billion, while CRM consumer experience increased 5.5% to $637.7 million and PR was up 2.3% organically to $356 million.

Broken down geographically, U.S. organic growth for Omnicom’s overall business was up slightly by 0.6% to $1.9 billion; U.K. revenue dropped by 0.3% to $357.3 million; and the Asia-Pacific market experienced 13.6% organic growth to $437.9 million. Latin American revenue increased 1.7% organically to $102 million, and the Middle East and Africa decreased 0.4% to $63.7 million in Q3.